NAS:APLT (USA) Also Trade In: Germany
Applied Therapeutics Inc $ 21.83 -0.06 (-0.27%)
Warning! GuruFocus has detected 1 Medium warning sign with APLT. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for APLT (Applied Therapeutics Inc) from 2019 to Jan 20 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Applied Therapeutics stock (APLT) PE ratio as of Jan 20 2021 is 0. More Details
Applied Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Applied Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:ENTA NAS:SRNE NAS:ARCT NAS:PASG NYSE:MYOV NAS:AIMT NAS:ODT NAS:RCKT NAS:ESPR NAS:ARQT OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 545 Fifth Avenue, Suite 1400, New York, NY, USA, 10173
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.